FDA gives Genzyme/Sanofi MS drug Lemtrada 2nd look
This article was originally published in Scrip
Executive Summary
The FDA has given the supplemental biologics license application (sBLA) for Lemtrada (alemtuzumab) from Genzyme, a unit of Sanofi, a second chance to gain approval as a treatment for relapsing forms of multiple sclerosis.